331. Idiopathic multicentric castleman disease Clinical trials / Disease details
Clinical trials : 33 / Drugs : 41 - (DrugBank : 21) / Drug target genes : 22 - Drug target pathways : 123
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2100048364 | 2021-09-01 | 2021-07-06 | A single-arm, prospective, and multicenter study of rituximab combined with lenalidomide in Castleman disease | A single-arm, prospective, and multicenter study of rituximab combined with lenalidomide in Castleman disease | Castleman disease | Treatment group:Rituximab+lenalidomide; | Department of Hematology, Jiangsu Provincial People's Hospital | NULL | Pending | 14 | 90 | Both | Treatment group:20; | Phase 4 | China |